Coldstream Capital Management’s RxSight RXST Stock Holding History

Coldstream Capital Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16	Closed	-$404	–	2901
2025 Q1	$404	Buy	+16	New	+$475	﹤0.01%	3397

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coldstream Capital Management's RXST Position: Q2 2025 in Review

Coldstream Capital Management sold out of RxSight (RXST) in Q2 2025, closing a stake of 16 shares — an estimated $404 sold.

Coldstream Capital Management first reported a position in RXST in Q1 2025 and held it in 1 quarter. The position peaked at $404 in Q1 2025. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

Coldstream Capital Management reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
Coldstream Capital Management sold 16 RxSight shares in Q2 2025, an estimated $404.
Coldstream Capital Management first reported a position in RxSight in Q1 2025 and held it in 1 quarter.
Coldstream Capital Management's RxSight position peaked at $404 in Q1 2025.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.